Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 24

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 24
---
005) filed on February 14, 2025, pursuant to Rule 462(b) as promulgated
under the Securities Act of 1933, as amended. The Offering closed on February 19, 2025, and the aggregate gross proceeds from the
Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company.

Series A Warrants

The following summary of certain terms and provisions of the Series A Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Series A Warrant, the form of which was filed as an exhibit to the Current Report on Form 8-K filed by the Company on February 21, 2025. Our security holders entitled to vote on the Issuance Proposal should carefully review the terms and provisions of the form of Series A Warrant for a complete description of the terms and conditions of the Series A Warrants.

Duration and Exercise Price

Each Series A Warrant is exercisable
for 0.25 share of Common Stock, has an exercise price equal to $0.48 per share, will become exercisable on (the “Initial
Exercise Date”) the first trading day following the date of the requisite stockholder approval (the “Stockholder
Approval”, and such date, the “Stockholder Approval Date”) and will expire on the fifth anniversary of such
Initial Exercise Date. The exercise price and number of shares of Common Stock issuable upon exercise of the Series A Warrants
is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our
Common Stock and the exercise price. The Series A Warrants were issued separately from the shares of Common Stock and/or
Pre-Funded Warrrants sold in the Offering and may be transferred separately immediately thereafter.

Exercise Price Adjustments

In addition, and subject to certain exemptions,
if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right
to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares
of Common Stock, at an effective price per share less than the exercise price of the Series A Warrants then in effect, the exercise
price of the Series A Warrants will be reduced to the lower of such price or the lowest VWAP during the five consecutive trading
days immediately following such